Introduction
Streptococcus pneumoniae and Streptococcus pyogenes are major infectious agents causing pneumonia, acute exacerbations of chronic bronchitis, pharyngitis, sinusitis, otitis media, bacteraemia, meningitis and other diseases. The development of resistance to penicillin G and macrolides in pneumococci is of increasing concern, especially that of multidrug-resistance. The fluoroquinolones were introduced in Europe in the 1980s and initially fulfilled the need to overcome the multidrug resistance at that time, and today they are still important in the treatment of a wide range of infections. In general, the prevalence of fluoroquinolone resistance in Europe is still low, 1 but resistance to many members of this class of agents is emerging in S. pneumoniae outside Europe.
Bacterial resistance to quinolones occurs mainly by alteration of their intracellular drug targets, the DNA topoisomerase IV and DNA gyrase enzymes. Genetic and biochemical studies have shown that fluoroquinolones target primarily topoisomerase IV and secondarily DNA gyrase in S. pneumoniae. 2, 3 Moreover, resistance mutations are localized in the quinolone resistancedetermining regions (QRDRs) of parC, parE and gyrA. Low-level quinolone-resistant strains usually harbour mutations altering the QRDR of one of the two subunits of topoisomerase IV: (i) S79 or D83 of parC or (ii) D435 of parE. This study examined the in vitro activity of the three quinolones WCK 771 [a novel arginine salt of the tricyclic fluoroquinolone S-(-)-nadifloxacin], WCK 1152 and WCK1153 (prepared by condensing 4-amino-or 4-hydroxy piperidines with known fluoroquinolone cores and subsequent optional derivatization) against selected clinical isolates of S. pneumoniae and S. pyogenes possessing different antibiotic resistance profiles ( Figure 1 ).
Materials and methods

Bacterial isolates
One hundred and fifty-nine isolates of S. pneumoniae and 52 isolates of S. pyogenes were chosen from the collection of the German National 
Susceptibility testing
MIC testing was performed using the broth microdilution method as recommended by the Clinical Laboratory Standards Institute (CLSI; formerly NCCLS). 4 Microtitre plates containing WCK 771, WCK 1152, WCK 1153 (all from Wockhardt Ltd, India) and comparators with cation-adjusted Mueller-Hinton broth (Oxoid, Wesel, Germany) plus 5% lysed horse blood (Oxoid) were used. S. pneumoniae ATCC 49619 was used as control strain.
Determination of resistance phenotypes and genotypes
For determination of macrolide-resistant phenotypes, discs (Oxoid Ltd, Basingstoke, UK) of erythromycin (15 mg) and clindamycin (2 mg) were placed 15 to 20 mm apart on Mueller-Hinton agar (BBL Microbiology Systems, Cockeysville, MD, USA) with 5% sheep blood (Oxoid, Wesel, Germany). Determination of macrolide-resistance genotypes was performed by a light cycler protocol as described previously. 5, 6 Nineteen pneumococcal isolates and one fluoroquinoloneresistant S. pyogenes isolate were randomly selected and analysed for alterations in the QRDRs. Prepared chromosomal DNA was used as a template for PCR amplification of target QRDRs. The primers and PCR conditions were those previously defined. 
Discussion
The spread of fluoroquinolone-resistant S. pneumoniae strains, despite worldwide prevalence being relatively low, is a concern to clinicians who manage respiratory tract infections. In a recent European multicentre study, a mean rate of fluoroquinolone resistance of 0.8% was reported (18 of 2279 pneumococcal strains), with the highest rates of resistance being in Italy (1.3%) and Portugal (1.2%). 1 To date, the level of fluoroquinolone resistance in S. pyogenes is low. 6 New fluoroquinolones have been developed to overcome resistance. WCK 771 is an arginine salt of the S-(-) isomer of nadifloxacin. Because the S-(-) isomer is primarily responsible for antibacterial activity, the potency of WCK 771 is two to four times higher than that of racemic nadifloxacin. The comparative assessment of WCK 771 with other fluoroquinolones demonstrated that this new agent is a highly potent antistaphylococcal fluoroquinolone with improved potency against even fluoroquinolone-resistant strains of S. aureus and coagulasenegative staphylococci. 8 In this study, an excellent level of in vitro activity against both S. pneumoniae and S. pyogenes streptococci was found for WCK 771 with low MIC 90 values (0.25-0.5 mg/L).
However, WCK 771 was less potent against highly ciprofloxacin-resistant S. pneumoniae, confirming findings of Appelbaum and co-workers who reported WCK 771 MIC 50 / MIC 90 values for 25 quinolone-resistant pneumococcal isolates Data on the in vitro activity of WCK 1152 and WCK 1153 are scarce. Both compounds were primarily developed for treatment of staphylococcal infections, including those by vancomycinand fluoroquinolone-resistant isolates. 8, 10 This study demonstrates that both compounds also showed excellent in vitro activity against antibiotic-resistant streptococci. Moreover, in contrast to WCK 771, WCK 1152 and WCK 1153 were also highly active against fluoroquinolone-resistant S. pneumoniae. Of note, based on the MIC 90 values, both WCK 1152 (MIC 90 1 mg/L) and WCK 1153 (MIC 90 0.5 mg/L) were up to eight times more active than moxifloxacin (MIC 90 4 mg/L) against ciprofloxacin-resistant pneumococcal isolates. The analysis of the in vitro activity of WCK 1152 and WCK 1153 against fluoroquinolone-resistant streptococci showed that the primary target seems to be DNA gyrase.
In summary, WCK 771 was potent against quinolonesusceptible S. pneumoniae in vitro, but not quinolone-resistant S. pneumoniae, regardless of penicillin G and macrolide susceptibility. WCK 1152 and WCK 1153 showed potency superior even to that of newer quinolones in clinical use against streptococci. Therefore, both are promising new agents having high potency against streptococci. If clinical studies yield a favourable safety profile, and if human pharmacokinetic studies support a susceptibility breakpoint of £2 mg/L, both compounds will be active against both quinolone-susceptible and quinolone-resistant streptococci, features not achieved by currently available quinolones. Activity of new quinolones against S. pneumoniae and S. pyogenes
